We have exclusive worldwide access to a nanodelivery platform, which significantly enhances delivery of drugs into cells and tissues. We are using this to create safe, effective “nanomedicines” with which to treat a number of serious unmet medical needs. Our priority is to develop effective therapies to treat onychomycosis (fungal nail infection). In addition, we are developing a number of exciting new therapies to treat infection and inflammation.
Blueberry operates with a highly experienced drug discovery and development team who have taken medicines from initial idea to the market. Our team collaborates with a range of academic and industrial partners and outsource providers to deliver our programs of work.